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2019 Community-acquired Pneumonia Treatment
Guidelines: There Is a Need for a Change toward More
Parsimonious Antibiotic Use
To the Editor:
The American Thoracic Society (ATS) and the Infectious
Diseases Society of America (IDSA) recently published updated
guidelines for the diagnosis and treatment of adults with community-
acquired pneumonia (CAP) (1). In the 12 years since the previous
edition of the guidelines was published, the importance of
incorporating antimicrobial stewardship principles into treatment
guidelines has been increasingly recognized (2). In 2017, the U.S.
Healthcare Infection Control Practices Advisory Committee
provided guidance regarding this issue for U.S. treatment guidelines.
One of the recommendations states that “when multiple therapeutic
options are available, a hierarchy of antibiotic treatment
recommendations should be provided with ‘first choice’ options
being those with adequate therapeutic efficacy, the lowest risk of
facilitating antimicrobial resistance, and the lowest risk of promoting
C. difficile and other adverse events, with consideration of healthcare
value” (3). The World Health Organization (WHO) recently
developed the AWaRe (Access, Watch, and Reserve) framework for
classifying antibiotics based on antibiotic stewardship principles, and
recommends its use in treatment guidelines (4, 5).
We are therefore concerned that the 2019 version of the
ATS/IDSA CAP guidelines seems to give disappointingly little
weight to such antibiotic stewardship principles while continuing to
recommendWHOWatch andReserve antibiotics as first-line options for
CAP inmost of the target populations.We suggest that Access antibiotics
would be sufficient for many patients and would be preferable from an
antibiotic stewardship perspective. Amoxicillin, which is the first-choice
treatment for CAP based on the 2019 WHO Model List of Essential
Medicines, and is also listed as a first-choice option in many guidelines
outside the United States, is only recommended in the ATS/IDSA
guidelines, together with doxycycline and macrolides as equivalent
options, for patients without comorbidities (very broadly stated as
“chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism;
malignancy; or asplenia”) (6, 7).
In the United States, 6 in 10 adults have one chronic disease,
and 4 in 10 adults have two or more chronic diseases, so the
recommendation for amoxicillin will be applicable to a minority of
adults with CAP (8). Therefore, U.S. physicians will most likely
continue to treat many patients with the Watch group respiratory
fluoroquinolones, a class of antibiotics with a well-documented
propensity to favor the emergence and spread of antibiotic
resistance and Clostridioides difficile infections, as well as an
increased risk of adverse events (U.S. Food and Drug
Administration alert) (9, 10).
This will hamper the CDC’s efforts to reduce overall
antibiotic consumption and fluoroquinolone use in the United
States (11). The Healthcare Infection Control Practices Advisory
Committee also suggested that guidelines should include
recommendations to educate patients about antibiotic therapy
when appropriate. Accordingly, the developers of the CAP
guidelines could have considered providing guidance to
physicians regarding the use of Access group antibiotics such
as amoxicillin and doxycycline in select patients with stable
comorbid conditions, along with close monitoring and adequate
patient education.
Even more surprising is the listing of the Reserve group fifth-
generation cephalosporin ceftaroline as a first-choice empiric
treatment option for CAP (in combination with a macrolide) in
hospitalized adults without risk factors for methicillin-resistant
Staphylococcus aureus and Pseudomonas aeruginosa. Efficacy data
from phase III trials suggesting that ceftaroline is superior to
ceftriaxone with regard to clinical cure require further scrutiny, and
its current listing as a first-choice option violates basic antibiotic
stewardship considerations (12, 13).
Given that respiratory tract infections are one of the most
frequent reasons for antibiotic prescriptions worldwide, and that in
many countries the U.S. treatment recommendations are still
considered an important reference, it seems to us, as members of the
WHO EML Antibiotics Working Group, that this represents a lost
opportunity for antibiotic stewardship. We believe there is a clear
need to better align all treatment guidelines to the same guiding
principles, and to establish a global set of evidence-based
recommendations with a focus on enhancing the use of Access
group antibiotics. n
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Reply to Huttner et al.
From the Authors:
We appreciate this additional letter submitted in response to the
recently published guidelines for the treatment of community-
acquired pneumonia (CAP) in adults (1).
Huttner and colleagues emphasize the importance of
antimicrobial stewardship principles in shaping antibiotic treatment
guidelines. We strongly agree. The adult CAP guideline emphasizes
that when multiple options are presented the final antibiotic choice
should be influenced by local and individual patient factors. We
also emphasized the importance of deescalating antibiotics when
appropriate and limiting the duration of antibiotic therapy. However,
our highest priority was to assure that adequate empiric treatment
is provided, especially for patients with more severe CAP. We
did recommend amoxicillin as monotherapy for uncomplicated
outpatients, but the recommendation for expanded antibiotic therapy
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